NASDAQ:SGEN

Seagen Competitors

$142.85
-1.62 (-1.12 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$140.83
Now: $142.85
$144.33
50-Day Range
$137.51
MA: $147.98
$158.62
52-Week Range
$117.91
Now: $142.85
$213.94
Volume497,744 shs
Average Volume1.17 million shs
Market Capitalization$25.90 billion
P/E Ratio56.24
Dividend YieldN/A
Beta1.11

Competitors

Seagen (NASDAQ:SGEN) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying SGEN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Seagen, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 87.2% of Seagen shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 31.1% of Seagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Amgen and Seagen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.14$7.84 billion$14.8216.80
Seagen$916.71 million28.25$-158,650,000.00($1.33)-107.41

Amgen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Amgen and Seagen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen0101402.58
Seagen161112.63

Amgen presently has a consensus target price of $259.4091, suggesting a potential upside of 4.20%. Seagen has a consensus target price of $185.3571, suggesting a potential upside of 29.76%. Given Seagen's stronger consensus rating and higher probable upside, analysts plainly believe Seagen is more favorable than Amgen.

Profitability

This table compares Amgen and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Seagen25.34%20.46%16.67%

Risk and Volatility

Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Summary

Seagen beats Amgen on 9 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 87.2% of Seagen shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 31.1% of Seagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Gilead Sciences and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Seagen25.34%20.46%16.67%

Valuation and Earnings

This table compares Gilead Sciences and Seagen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.65$5.39 billion$6.1410.60
Seagen$916.71 million28.25$-158,650,000.00($1.33)-107.41

Gilead Sciences has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Gilead Sciences and Seagen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191402.54
Seagen161112.63

Gilead Sciences presently has a consensus target price of $97.2308, suggesting a potential upside of 49.33%. Seagen has a consensus target price of $185.3571, suggesting a potential upside of 29.76%. Given Gilead Sciences' higher probable upside, research analysts plainly believe Gilead Sciences is more favorable than Seagen.

Summary

Seagen beats Gilead Sciences on 8 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Vertex Pharmaceuticals38.51%28.55%20.68%

Earnings and Valuation

This table compares Seagen and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million28.25$-158,650,000.00($1.33)-107.41
Vertex Pharmaceuticals$4.16 billion13.32$1.18 billion$4.2949.73

Vertex Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seagen and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
Vertex Pharmaceuticals042112.88

Seagen presently has a consensus target price of $185.3571, indicating a potential upside of 29.76%. Vertex Pharmaceuticals has a consensus target price of $293.1250, indicating a potential upside of 37.39%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Seagen.

Summary

Vertex Pharmaceuticals beats Seagen on 10 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Earnings and Valuation

This table compares Seagen and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million28.25$-158,650,000.00($1.33)-107.41
Regeneron Pharmaceuticals$7.86 billion6.47$2.12 billion$21.4722.13

Regeneron Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seagen and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
Regeneron Pharmaceuticals051412.80

Seagen presently has a consensus target price of $185.3571, indicating a potential upside of 29.76%. Regeneron Pharmaceuticals has a consensus target price of $637.2083, indicating a potential upside of 34.10%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Seagen.

Summary

Regeneron Pharmaceuticals beats Seagen on 9 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Biogen35.63%51.00%23.54%

Earnings and Valuation

This table compares Seagen and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million28.25$-158,650,000.00($1.33)-107.41
Biogen$14.38 billion2.84$5.89 billion$33.577.99

Biogen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seagen and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
Biogen5141202.23

Seagen presently has a consensus target price of $185.3571, indicating a potential upside of 29.76%. Biogen has a consensus target price of $303.5517, indicating a potential upside of 13.19%. Given Seagen's stronger consensus rating and higher possible upside, analysts clearly believe Seagen is more favorable than Biogen.

Summary

Seagen beats Biogen on 8 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Alexion Pharmaceuticals16.32%23.16%14.76%

Earnings and Valuation

This table compares Seagen and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million28.25$-158,650,000.00($1.33)-107.41
Alexion Pharmaceuticals$4.99 billion6.83$2.40 billion$9.7415.91

Alexion Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seagen and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
Alexion Pharmaceuticals017512.30

Seagen presently has a consensus target price of $185.3571, indicating a potential upside of 29.76%. Alexion Pharmaceuticals has a consensus target price of $153.8636, indicating a potential downside of 0.74%. Given Seagen's stronger consensus rating and higher possible upside, analysts clearly believe Seagen is more favorable than Alexion Pharmaceuticals.

Summary

Seagen beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.


Seagen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$248.95-0.8%$143.35 billion$23.36 billion20.08Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.11-0.1%$81.98 billion$22.45 billion67.12
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$213.35-1.4%$55.46 billion$4.16 billion26.94Insider Selling
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$475.17-0.3%$50.91 billion$7.86 billion17.37News Coverage
Biogen logo
BIIB
Biogen
1.9$268.17-0.9%$40.85 billion$14.38 billion8.88
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$155.01-0.3%$34.08 billion$4.99 billion36.22
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.54-2.4%$21.23 billion$876.29 million-56.81Gap Down
Incyte logo
INCY
Incyte
1.9$79.96-1.1%$17.58 billion$2.16 billion-50.93News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.23-3.1%$16.22 billion$219.75 million-17.65News Coverage
Gap Down
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.07-1.5%$14.01 billion$1.70 billion17.64Insider Selling
News Coverage
Novavax logo
NVAX
Novavax
1.6$179.74-1.9%$13.28 billion$18.66 million-34.43Insider Selling
Gap Up
Repligen logo
RGEN
Repligen
1.5$206.10-0.9%$11.29 billion$270.24 million251.34News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.36-1.3%$9.06 billion$1.45 billion19.24Analyst Report
Analyst Revision
News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.35-0.7%$8.77 billion$788.10 million100.38Analyst Downgrade
Exelixis logo
EXEL
Exelixis
1.9$23.12-1.0%$7.21 billion$967.78 million48.17
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.77-1.3%$6.13 billion$195.99 million267.31
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.16-1.1%$2.12 billion$638.60 million-10.83
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21-1.9%$1.81 billion$48.83 million-13.43
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Gap Down
Codexis logo
CDXS
Codexis
1.1$24.00-2.6%$1.55 billion$68.46 million-68.57Insider Selling
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02Gap Down
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19-2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$20.71-1.4%$820.43 million$3.57 million-9.29Analyst Upgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
Agenus logo
AGEN
Agenus
1.6$2.79-0.0%$570.05 million$150.05 million-2.56
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Verastem logo
VSTM
Verastem
1.1$2.76-1.8%$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07-3.9%$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48-2.7%$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23-0.4%$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
XOMA logo
XOMA
XOMA
1.3$38.99-0.8%$438.75 million$18.37 million-35.13Analyst Upgrade
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.